Urine Biomarker Discovery for IBD

Urine is a further biological fluid becoming increasingly important for biomarker studies and development in inflammatory bowel diseases (IBD). Urine has several advantages over other biological samples, including its very simple and non-invasive collection, its low dynamic range of proteins as it contains a lower abundance of proteins than blood, and the high stability of the sample, which allows reproducible determinations.

Fig. 1. Urinary biomarkers may provide superior diagnostic capabilities compared to serum biomarkers in specific diseases. Fig. 1. Urine biomarkers can outperform serum biomarkers in certain diseases. (Galipeau et al., 2021)

Urine Biomarker Discovery Services

Ace Therapeutics' biomarker and translational research platform provides a flexible, fit-for-purpose strategy from urine biomarker discovery to preclinical application in IBD drug development. Our biomarker discovery services provide excellent support to help you maximize your urine sample analysis.

The platform provides urine biomarker detection (including cytokines, inflammatory factors, and chemokine combinations), pathology analysis (multiplex immunohistochemistry, multiplex immunofluorescence, in situ hybridization, fluorescence in situ hybridization), genomics studies (next-generation sequencing, single-cell sequencing, CITE-seq), proteomics and spatial genomics, and in vivo target action.

Technologies We Use

Leveraging our expertise in applied omics technologies, we can reveal molecular pathways by quantifying differentially expressed molecules associated with different pathological conditions and identify urine biomarkers in animal models of IBD. We aim to provide data support support for IBD characterization, diagnosis, and prediction of treatment response.

Metabolomics Technologies	Our nuclear magnetic resonance (NMR) and mass spectrometry (MS) analytical platforms support the identification of metabolite changes in urine in the early stages of IBD, allowing specific metabolites to be investigated and analyzed, thus helping our clients to discover urine biomarkers and deepen their understanding.
Proteomics Technologies	We utilize mass spectrometry to analyze and measure all identifiable proteins in urine, assisting our clients in the discovery of biomarkers for IBD with exceptional sensitivity and specificity. Furthermore, we provide antibody-based immunoassays and mass spectrometry assays for the quantification of urine biomarkers to support validation efforts.

Metabolites in Urine You May Be Interested In

Citric acid cycle intermediates	Butyrate	Phenylacetate	2-(4-hydroxyphenyl) propanoic acid	Methylamine
Phenylacetylglycine	Indoxyl sulfate	Hippurate,	4-cresol sulfate	Adipate
Azelate	N methylnicotinate	Methyguanidine	4-cresol glucuronide	Phenyl-acetylglycine
p-cresol glucuronide)	Bile acid 12a-hydroxy-3-oxocholadienic acid	4-(2-aminophenyl)-2,4-dioxobutanoic acid	4,6-cihydroxyquinoline	Hypoxanthine

Proteins in Urine You May Be Interested In

Carbonic anhydrase 1	Neutrophil collagenase	Neutrophil gelatinase-associated lipocalin	Beta-mannosidase
Glyceraldehyde-3-phosphate dehydrogenase	Ribonuclease pancreatic gamma-type	Sodium-dependent neutral amino acid transporter B(0)AT3	-

Based on advanced technology platforms and solid expertise, Ace Therapeutics helps pharmaceutical companies focused on IBD research to systematically and comprehensively characterize changes in proteins and metabolites in urine samples that are relevant for the identification of new biomarkers and disease states. If you are interested in our urine biomarker discovery services, please do not hesitate to contact us.

Reference

Xue, C., et al. (2023). Urine biomarkers can outperform serum biomarkers in certain diseases. Urine, 5, 57-64.

! For research use only, not intended for any clinical use.